These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

875 related items for PubMed ID: 25327734

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
    Tang XH, Lu MS, Deng S, Li M.
    Zhonghua Fu Chan Ke Za Zhi; 2019 Apr 25; 54(4):255-261. PubMed ID: 31006192
    [Abstract] [Full Text] [Related]

  • 4. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
    Tang XH, Deng S, Li M, Lu MS.
    Biochem Biophys Res Commun; 2012 Jun 15; 422(4):676-80. PubMed ID: 22609777
    [Abstract] [Full Text] [Related]

  • 5. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tang XH, Deng S, Li M, Lu MS.
    Tumour Biol; 2016 Apr 15; 37(4):5521-8. PubMed ID: 26572150
    [Abstract] [Full Text] [Related]

  • 6. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
    Tang XH, Li M, Deng S, Lu MS.
    Anticancer Drugs; 2014 Nov 15; 25(10):1201-10. PubMed ID: 25115341
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
    Fan LL, Chen X, Zhang XY, Li ZM, Fan XM, Shen Y.
    Med Sci Monit; 2020 Aug 23; 26():e922612. PubMed ID: 32829374
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
    Dateoka S, Ohnishi Y, Kakudo K.
    Med Mol Morphol; 2012 Jun 23; 45(2):91-7. PubMed ID: 22718294
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Effect of estrogen or progesterone combined with paclitaxel on human ovarian cancer cell growth and Drosha expression].
    Yang Y, Han K, Xie Y.
    Zhonghua Zhong Liu Za Zhi; 2015 Aug 23; 37(8):578-84. PubMed ID: 26714597
    [Abstract] [Full Text] [Related]

  • 18. [Impact of cyclin-dependent kinase inhibitor p27 on resistance of ovarian cancer multicellular spheroids to taxol].
    Xing H, Li J, Gao QL, Wu JH, Gao C, Lu YP, Ma D.
    Zhonghua Yi Xue Za Zhi; 2003 Jan 10; 83(1):37-41. PubMed ID: 12757643
    [Abstract] [Full Text] [Related]

  • 19. Octreotide reverses the resistance of A2780/Pacliaxel ovarian cancer cell line to paclitaxel chemotherapy in vitro.
    Shen Y, Zhang XY, Chen X, Ren ML, Cai YL.
    J Cancer Res Ther; 2016 Jan 10; 12(2):657-62. PubMed ID: 27461627
    [Abstract] [Full Text] [Related]

  • 20. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
    Shi XY, Cai XJ, Lei JX, Cao FJ, Pan DF, Chen P.
    Ai Zheng; 2008 Apr 10; 27(4):343-7. PubMed ID: 18423117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.